Latest Pharmaceutical Companies News

Zoono Group Limited reports strong progress in its shelf-life extension technology with 50 active trials worldwide and anticipates its first significant sales this quarter, supported by fresh funding and expanding market interest.

Bioxyne Limited has reported a record-breaking first quarter for FY26, with revenues soaring 210% year-on-year, driven by strong demand in cannabis products and strategic European market advances.

Clever Culture Systems reports a cashflow positive quarter, expanding its pharmaceutical customer base and launching a new contact plate analysis module that promises to drive recurring revenues.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.

MedAdvisor reports a sharp 53% drop in 1Q FY26 revenue driven by U.S. regulatory and sector challenges, while advancing a major platform transformation and selling its ANZ business to emerge debt-free.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

Mayne Pharma has announced the rescheduling of its Supreme Court hearing to November 3, 2025, to approve the acquisition scheme by Cosette Australia BidCo, pending Foreign Investment Review Board approval.

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.

Wellnex Life Limited has expanded its financing with a new A$2.5 million loan facility, enhancing its financial flexibility to support ongoing business growth and settle long-term obligations.

4DMedical has secured multi-year agreements to deploy its advanced lung imaging technology across Brazil and Australia, supporting national lung cancer screening programs and enhancing lung health diagnostics.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.